ArticleBMJ open2025

Obinutuzumab versus Rituximab to maintain remission in children with steroid-dependent and frequently relapsing nephrotic syndrome: the OBIRINS study protocol, a double-blind randomised controlled trial.

Claire Dossier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.